Gary Hao is currently the Vice President of CMC at ClimbBio, overseeing critical biopharmaceutical development. Previously, they held various senior positions, including Vice President of CMC at Vesigen Therapeutics and Director of Biologics CMC at TG Therapeutics. Gary has a robust background in CMC development, with experience at Progenics Pharmaceuticals, Inc., Merck Group, Alkermes, and Codiak BioSciences. They hold a Bachelor of Science in Biochemistry from Nankai University and are pursuing a Doctor of Philosophy in Pharmacology from Joan & Sanford I. Weill Medical College of Cornell University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices